FLC: Distribution Secure For Another Quarter, A Relative Value
Last time we touched on FLC, they had trimmed their distribution a bit. They are focused on sustainability and…
Pfizer And Merck: Two Long-Term Laggards In A Momentum Market, As Pfizer Gets A Catalyst From Covid-19
Pfizer traded up to its May ’99 all-time-high this week after lagging for 21 years. Merck traded up to…
Columbia Care: No Reason For Dip
Columbia Care reported strong growth in Q2 and topped $100 million in quarterly revenue. The MSO has massive scale…
Uber And Lyft: The Limits Of The Amazon Model
The Amazon business model of undercharging and overproducing to gain scale at the expense of profits is beginning to…
Metalla Royalty & Streaming: Valuation Still An Issue
Metalla Royalty & Streaming released its fiscal Q2 2021 results last week, reporting quarterly revenue of $0.70 million, and…
Texas Instruments: Subscription-Like Hardware
Analog is a subscription-like business with consistent revenue from long-lasting and low-churn products. Analog is built on older…
Incyte: Undervalued And Expecting FDA Feedback In H2 2021
Incyte Corp is a biopharmaceutical company conducting both commercial and clinical development operations.
RYLD: Small-Cap Covered Call ETF, 11.0% Dividend Yield, Strong Returns
RYLD is a small-cap covered call ETF, yields 11.0%, and is a buy. Here’s an overview of the fund,…
Revance Therapeutics: Frowning At The FDA
Despite the recent selloff, shares of Revance Therapeutics are up 65% since I gave a very bullish recommendation 2…
Yamana Gold: Getting Better
Yamana Gold reported its second-quarter 2021 results on July 29, 2021. Check out my price recommendation for buying AUY…
recent post
-
Nov 11 2025 -
Nov 11 2025
-
Nov 11 2025
-
Nov 11 2025
-
Nov 11 2025
